Cambridge Healthtech Institute’s Inaugural
Peptide and Oligo Manufacturing
Towards Scalable, Sustainable Production
10-11 March 2026
Rising global demand for peptides and oligonucleotides is pushing the industry to innovate with manufacturing approaches that balance both scale and sustainability. Cambridge Healthtech Institute’s Inaugural Peptide and Oligo Manufacturing conference brings together experts from the worlds of bioprocessing and process chemistry to explore the latest developments in synthetic, hybrid, and recombinant production platforms to improve the production of therapeutic peptides, antimicrobials, ASOs, siRNAs, and more. Sessions will address advances in upstream and downstream processes, expression systems, continuous purification, green chemistry, drug product and formulation, and overcoming challenges with conjugated and non-canonical molecules. Examples come from therapeutic peptides, antimicrobials, ASOs, siRNAs, and more.
Coverage will include, but is not limited to:
- Global Trends in Peptide & Oligonucleotide Manufacturing – market drivers, major players, and environmental impacts
- Recombinant Production Approaches – scalability and sustainability for peptides, oligos, and GLP-1 agonists
- Lessons from Insulin & Recombinant Proteins – applying historical insights to novel therapeutics
- Synthetic vs. Hybrid Strategies – innovations in SPPS, enzyme ligation, and incorporation of non-canonical amino acids
- Green Chemistry in Manufacturing – reducing solvents, waste, and energy use in chemical manufacturing
- Advances in Expression Systems – E. coli, yeast, and fermentation platforms
- Downstream Processing Innovations – purification of peptides, conjugates, and oligos, including MCSGP and impurity removal
- Continuous Manufacturing – enabling efficiency and scalability in recovery and purification workflows
- Formulation & Drug Delivery – improving stability, bioavailability, and high-concentration formulations
- AI/ML in Therapeutic Design and Manufacturability – leveraging predictive tools to optimise drug properties and improve manufacturability
- Immunogenicity Risk Management – strategies to assess and mitigate risks across the product lifecycle
The deadline for priority consideration is Friday 12 September
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: